Key result
Smartwatch ECG devices lack proven accuracy and dosing guidance for QTc monitoring during antiarrhythmic therapy.
Why the study?
The accuracy and dosing discretion of wearable smartwatch ECG devices for QTc monitoring during antiarrhythmic drug therapy remain unknown.
Comparison
Smartwatch ECG QTc measurements vs 12-lead ECG QTc measurements
Answers are grounded in this paper and cite their sources.
Mobile ECG QTc correlation with 12-lead is poor during sotalol loading; leaves open role for extended AAD monitoring.
Sotalol and dofetilide initiation require inpatient hospitalization for serial 12L ECG monitoring of the corrected QT interval (QTc) to monitor risk of ventricular proarrhythmia. Wearable smartwatch ECG devices may support extended QTc monitoring beyond the initiation window, however their accuracy and dosing discretion during antiarrhythmic drug (AAD) therapy remain unknown.
No takes yet. Share an insight, caveat, or question.
Armas et al. (2026) studied this question. Smartwatch ECG devices have unknown accuracy and dosing discretion for QTc monitoring during antiarrhythmic drug therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: